Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 sonelokimab in moderate to severe hidradenitis suppurativa
2024-511363-28-00Phase 3Completed
- Sponsor
- MoonLake Immunotherapeutics
- Start
- Sep 2024
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 12
01
Overview
Phase 3, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing Sonelokimab with Placebo (2 arms). Primary endpoint: HiSCR75 at Week 16. Started Sep 2024; status: completed.
02
Drugs
sonelokimab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2024-511363-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511363-28-00.